濟川藥業(600566.SH)全資子公司與徵祥醫藥簽署獨家合作協議及投資意向書
格隆匯8月6日丨濟川藥業(600566.SH)發佈公吿,公司全資子公司濟川藥業集團有限公司(以下簡稱“濟川有限”)與南京徵祥醫藥有限公司(以下簡稱“徵祥醫藥”)簽署獨家合作協議及投資意向書,約定授予濟川有限在中國大陸地區對徵祥醫藥自主研發的一款用於治療或預防流感的聚合酶酸性蛋白(PA)抑制劑(代號為:ZX-7101A)口服制劑約定的適應症享有獨家推廣權益,濟川有限向徵祥醫藥支付不超過人民幣1.2億元(含税)的推廣權益對價,並擬以自有資金6000萬元向徵祥醫藥進行股權投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.